Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

Early Phase 1
2(66.7%)
Phase 2
1(33.3%)
3Total
Early Phase 1(2)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT06495814Phase 2Not Yet Recruiting

Characterization and Mechanism Research of the Pre-disease State of Obese Type 2 Diabetes Mellitus

Role: lead

NCT04711980Early Phase 1Unknown

Post-marketing Evaluation of Mudan Granule Intervention on Type 2 Diabetic Peripheral Neuropathy

Role: lead

NCT03025399Early Phase 1Unknown

Clinical Study of Tang Wang Prescription Intervene Diabetic Non-proliferative Retinopathy

Role: lead

All 3 trials loaded